Dutasteride vs MK-2866
FDA Approved vs Moderate Research
avoid Mechanism-based · 64% Both Dutasteride and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Dutasteride MK-2866
Weight 528.53 Da 389.33 Da
Half-life ~5 weeks (extremely long; active metabolite accumulation over months) ~24 hours
Type Synthetic 4-azasteroid compound (dual 5-alpha reductase inhibitor) Non-steroidal selective androgen receptor modulator (C19H14F3N3O3)
Key Benefits
Dutasteride
01 Inhibits both Type I and Type II 5-alpha reductase for more complete DHT suppression
02 Reduces serum DHT by approximately 90%, compared to 70% with finasteride
03 Head-to-head trials show superior hair count improvements over finasteride at 12 and 24 weeks
04 FDA-approved for BPH with well-established long-term safety data
05 Extremely long half-life allows for flexible dosing schedules (daily or 3x per week)
06 Convenient once-daily oral dosing with no injections required
07 Can be combined with minoxidil for enhanced hair loss treatment
MK-2866
01 Increases lean body mass in a dose-dependent manner with clinical trial support
02 Preserves muscle mass during caloric deficit or catabolic conditions
03 Selective tissue activity reduces androgenic side effects compared to anabolic steroids
04 Oral bioavailability eliminates the need for injections
05 Does not aromatize to estrogen, avoiding gynecomastia and water retention
06 Improves physical function and stair-climbing power in clinical populations
07 Long 24-hour half-life allows convenient once-daily dosing
08 Mild side effect profile at commonly studied doses
Side Effects
Dutasteride
Decreased libido (reported in 3-5% of men; somewhat higher incidence than finasteride due to greater DHT suppression)
Erectile dysfunction (reported in 3-5%; more frequently reported than with finasteride)
Decreased ejaculate volume (reported in 1-2%)
Gynecomastia or breast tenderness (reported in approximately 1-2%)
MK-2866
Mild testosterone suppression (dose-dependent, typically 10-30% reduction at 25 mg)
HDL cholesterol reduction (10-20% suppression observed in clinical trials)
Headaches, particularly during the first 1-2 weeks
Mild back pain or muscle cramps
Transient fatigue toward the end of longer cycles
Slight reduction in libido at higher doses or extended cycle lengths
Contraindications
Women who are pregnant or may become pregnant (dutasteride is teratogenic and can cause abnormalities of external genitalia in a male fetus; even handling damaged capsules poses a risk due to skin absorption)
Women who are breastfeeding
Known hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, or any component of the formulation
Severe hepatic impairment (dutasteride is extensively metabolized by the liver via CYP3A4)
Pediatric patients (not indicated for use in children)
Co-administration with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) may significantly increase dutasteride levels
Active liver disease or significantly elevated liver enzymes
Hormone-sensitive cancers (breast, prostate) without oncologist clearance
Pregnancy or breastfeeding (potential endocrine disruption to fetus/infant)
Individuals under 21 years of age (risk of premature HPTA disruption during development)
Concurrent use of hepatotoxic medications without liver function monitoring
Known hypersensitivity to MK-2866 or any formulation excipients
Competitive athletes subject to WADA or USADA anti-doping testing
Research Evidence
Dutasteride MK-2866
Status FDA Approved Moderate Research
References 5 studies 5 studies
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.